Mario Rovirosa – CEO, Ferrer
Ferrer’s CEO, Mario Rovirosa, outlines how he and a new management team have been building the foundation of the Spanish mid-cap’s transformation to become a specialty pharma company, a 180-degree…
Founded in 1959, Ferrer is a Spanish multinational privately-held pharmaceutical company headquartered in Barcelona with a presence in over 90 countries. They operate in the pharmaceutical, health, fine chemicals (API), and food sectors. The company has expertise in the fields of cardiology, central nervous system, dermatology, gastroenterology, metabolism, oncology, musculoskeletal system, paediatrics, pain management, and respiratory.
Ferrer’s CEO, Mario Rovirosa, outlines how he and a new management team have been building the foundation of the Spanish mid-cap’s transformation to become a specialty pharma company, a 180-degree…
Alejandro Mora, Ferrer’s country manager for Central America & Caribbean, discusses the complexity of the region’s healthcare systems, the company’s strategy to compete against local players, and the importance for…
Xavier Rams, General Director at Ferrer Mexico, explains the importance of aligning corporate strategy to public healthcare goals in order to succeed in the dynamic Mexican environment and showcases the…
CPH Pharma was the oldest running pharmaceutical company in Portugal until its acquisition by Grupo Ferrer in 2008. Since then, the company has continued to thrive in the marketplace despite…
Our business model is new in the Chilean market and enables us with great flexibility and allows us to focus on demand generation. For Ferrer this is a great window…
In the second part of a two-part interview, Generika Philippines co-founders, Teodoro Ferrer and Julien Bello, go on to discuss the future of generic medicines in the Philippines, the compnay’s…
In part one of a two-part interview, Generika Philippines co-founders Teodoro Ferrer and Julien Bello discuss what led them to start the company, the changing mentality among the Filipino population…
The latest from Spanish pharma, including the wide swathe of COVID-19 syringes, vaccines, masks, and tests being produced in the country, Grifols’ Egyptian entry, a new generation of leadership at…
A roundup of the latest news from Spanish pharma, including J&J’s COVID-19 vaccine trial, the latest developments at Spanish firm PharmaMar which hopes its Aplidin can be used as a…
PharmaMar, a Spanish firm, is beginning Phase II clinical trials for its anti-tumour drug Aplidin to treat coronavirus. The firm’s stocks have soared on the news. PharmaMar is joining…
Building on the topics covered in our March 2019 report, the latest edition of Healthcare & Life Sciences Review Spain takes a closer look at the broader Spanish life sciences…
Juan Carlos Moro Rodríguez, CEO for the Iberia Cluster with DB Schenker, discusses the company’s plans to expand its reach across all forms of transport, offering logistics solutions rather than…
Though still one of the younger and lesser-known outfits inhabiting the European drug development landscape, Irish-headquartered rare disease specialist, Jazz pharma has been making tremendous headway in the onco-haematology and…
In what is a highly competitive and crowded women’s health field in Spain, smaller players are having to be increasingly focused and specialised to carve out a market share. …
Many of the world’s mega-rich are increasingly active philanthropists in the healthcare arena and Spain is no exception with Galician billionaire Amancio Ortega Gaona, the 82-year-old owner of clothing empire…
The global acquisition of GSK’s thrombosis portfolio and subsequent purchase of AstraZeneca’s anaesthesia business have been critical milestones for the maverick South African pharmaceutical outfit Aspen, enabling the company to…
Perhaps the only CEO of a dermo-cosmetics company with a PhD in astrophysics and space technology as well as three years working at NASA under his belt, Isdin’s Juan Naya…
The North-Eastern region of Catalonia is one of Spain’s most prosperous and has been allocating increasingly large amounts of its budget towards healthcare. With strong government backing and a robust…
Rocco De Bernardis, managing director for Johnson & Johnson Medical Devices in Spain offers his insights into the company’s local footprint, assesses the situation for value-based healthcare implementation in Spain…
See our Cookie Privacy Policy Here
